Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. (NYSE: NUVB) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its oncology business, financial position and key agreements. On this page, you can review NUVB’s current reports on Form 8‑K and other SEC filings alongside AI-generated summaries that help explain the significance of each document.
For Nuvation Bio, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources for information on its pipeline of targeted cancer therapies, including taletrectinib (IBTROZI) for ROS1-positive non-small cell lung cancer, safusidenib for IDH1-mutant gliomas, NUV-868 and its drug-drug conjugate platform. These filings typically describe clinical programs such as the TRUST registrational studies for taletrectinib and the G203 study for safusidenib, as well as risk factors relevant to oncology drug development and commercialization.
Nuvation Bio also uses Form 8‑K to disclose material events. Recent 8‑K filings have reported preliminary financial results and net product revenue for IBTROZI, the entry into a license and collaboration agreement with Eisai Co., Ltd. for taletrectinib in multiple territories, publication of positive Phase 2 data for safusidenib, and strategic decisions such as discontinuation of NUV-1511 while continuing the underlying DDC platform. Other 8‑Ks have furnished earnings press releases and updated corporate presentations.
Investors interested in equity structure and trading can consult registration statements and periodic reports for details on Nuvation Bio’s Class A common stock and redeemable warrants, which trade on the New York Stock Exchange under the symbols NUVB and NUVB.WS. Form 4 insider transaction reports, when available, can be used to track purchases and sales of NUVB securities by directors and officers.
Stock Titan enhances access to these filings with AI-powered summaries that highlight key terms in complex agreements, explain financial disclosures in plain language and point out important milestones, such as collaboration payments or changes in clinical program status. Real-time updates from EDGAR ensure that new NUVB filings appear promptly, while structured views of 10‑K, 10‑Q, 8‑K and Form 4 documents help users quickly locate the information most relevant to their analysis of Nuvation Bio’s oncology business.
Nuvation Bio Inc. (NUVB) reported an insider equity transaction by its Chief Medical Officer. On 11/20/2025, the officer exercised a stock option to buy 20,000 shares of Class A common stock at $1.87 per share and then sold 20,000 shares of Class A common stock in an open-market transaction at a weighted-average price of $7.0037 per share. After these transactions, the officer beneficially owned 18,000 shares of Class A common stock directly and held 450,000 stock options with an exercise price of $1.87 per share, expiring on 02/27/2034. The option vests 25% on the one-year anniversary of 02/29/2024 and monthly over the following 36 months, subject to continuous service.
Nuvation Bio Inc. (NUVB)11/19/2025, the officer exercised 200,000 stock options at an exercise price of $1.87 per share, converting them into Class A common stock. On the same date, the officer sold 200,000 Class A common shares at a weighted-average price of $7.1384 per share. After these transactions, the officer directly held 24,000 shares of Class A common stock and 300,000 stock options. The filing notes additional shares acquired through the company’s 2021 Employee Stock Purchase Plan and describes the vesting schedule for the option grant.
A shareholder of NUVB has filed a Rule 144 notice to sell up to 369,051 common shares through broker Morgan Stanley Smith Barney LLC on the NYSE. The filing lists an aggregate market value of
An affiliate of NUVB has filed a Form 144 notice to sell 20,000 shares of Class A common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $140,074.00. The filing lists 342,833,433 shares of Class A common stock outstanding and shows that the 20,000 shares were acquired on 11/20/2025 by exercising options under a registered plan for cash. The seller, Dongfang Liu, also sold 15,000 Class A shares on 11/17/2025 and 15,000 shares on 11/19/2025 in the prior three months.
Nuvation Bio Inc. (NUVB) reported insider transactions by its Chief Medical Officer on Form 4. On 11/17/2025 and 11/19/2025, the officer exercised stock options to buy a total of 30,000 shares of Class A common stock at an exercise price of $1.87 per share and sold 30,000 shares in open-market transactions.
The sales included 15,000 shares on 11/17/2025 at $4.765 per share and 15,000 shares on 11/19/2025 at a weighted-average price of $5.1035 per share. After these transactions, the officer beneficially owned 18,000 shares of Class A common stock and held 470,000 stock options with a $1.87 exercise price expiring on 02/27/2034.
NUVB shareholder files notice to sell common shares under Rule 144. A holder of Class A common stock plans to sell 15,000 shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $76,552.50. These shares were acquired on 11/19/2025 by exercising options under a registered plan for cash and will be sold as freely tradable stock. The notice also reports a prior sale over the past three months of 15,000 Class A common shares on 11/17/2025 for gross proceeds of $71,475. The form includes a representation that the selling holder is not aware of any undisclosed material adverse information about NUVB’s operations.
NUVB Form 144 shows a planned insider sale of common stock. A holder has filed notice to sell 200,000 shares of Nuvation Bio common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,427,680.00. The shares are listed for sale on the NYSE with an approximate sale date of 11/19/2025. As of the filing, 342,833,433 shares of Nuvation Bio common stock were outstanding, which is a baseline figure for the company’s equity. The shares to be sold were acquired on 11/19/2025 by exercising stock options under a registered plan and paid for in cash.
Nuvation Bio Inc. released an updated corporate presentation and highlighted newly published positive Phase 2 data for its IDH1 inhibitor safusidenib in Japanese patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. In an open-label study of 27 patients, safusidenib achieved an objective response rate of
Adverse events were mostly mild to moderate; grade 3 or higher treatment-related events occurred in
NUVB filed a Form 144 notice for a proposed sale of its Class A common stock. The filing covers a planned sale of 15,000 Class A common shares on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $71,475. These 15,000 shares were acquired on 11/17/2025 by exercising stock options under a registered plan, paid for in cash on the same date. The filing notes that 342,833,433 shares of Class A common stock were outstanding, providing context for the size of the planned sale.
Nuvation Bio (NUVB) reported Q3 2025 results. Total revenue was $13.1 million versus $0.7 million a year ago, driven by the first commercial sales of IBTROZI in the U.S. Product revenue was $7.7 million, and collaboration and license revenue was $5.4 million. Cost of revenue was $3.3 million, yielding gross profit of $9.8 million.
Operating expenses were $66.2 million (R&D $28.8 million; SG&A $37.4 million). Loss from operations was $56.4 million and net loss was $55.8 million ($0.16 per share). Weighted average shares outstanding were 342.4 million.
Liquidity remained significant with $549.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025. During the nine months, the company received $150.0 million from a revenue interest financing agreement and $48.9 million in borrowings; operating cash outflow was $143.7 million. Total liabilities rose to $275.7 million, including $150.6 million related to the revenue interest financing and $47.1 million in long-term borrowings. IBTROZI began U.S. shipments in June 2025.